Two medicines, side by side
Acetaminophen/oxycodone vs amlodipine/valsartan
Acetaminophen/oxycodone is labeled for pain; amlodipine/valsartan for high blood pressure. Their labels share no use, so they are not alternatives to each other. Drugs@FDA records approvals of acetaminophen/oxycodone since 2014 and of amlodipine/valsartan since 2007. Pharmacies paid $0.183 per oxycodone-acetaminophen 7.5-325 mg tablet and $0.330 per unit (Amlodipine-valsartan 10-160 mg) (NADAC, October 7, 2026); the strengths differ, so the two prices are not like for like. In FDA's classes, acetaminophen/oxycodone is an opioid agonist and amlodipine/valsartan a calcium channel blocker.
Check it at the source: the acetaminophen/oxycodone FDA label on DailyMed (effective December 23, 2025); the amlodipine/valsartan FDA label on DailyMed (effective February 17, 2026).
Highlights of the acetaminophen and oxycodone record
Acetaminophen and oxycodone (Percocet) · label of December 23, 2025
ADDICTION, ABUSE, AND MISUSE: RISK EVALUATION AND MITIGATION STRATEGY (REMS); LIFE-THREATENING RESPIRATORY DEPRESSION; ACCIDENTAL INGESTION; NEONATAL OPIOID WITHDRAWAL SYNDROME;
Used for
From the label: indicationsOxycodone and acetaminophen tablets are indicated for the management of pain severe enough to require an opioid analgesic and for which alternative treatments are inadequate. […]
On the market
- Earliest approval on file
- March 11, 2014
- Generic labelers
- 29 labelers
- Pharmacy cost
- $0.183 per tablet
Supply and safety
- Shortage
- A presentation being discontinued
- Recalls
- 8
Highlights of the amlodipine and valsartan record
Amlodipine and valsartan (Exforge) · label of February 17, 2026
FETAL TOXICITY When pregnancy is detected, discontinue Exforge as soon as possible. (5.1) Drugs that act directly on the renin-angiotensin system can cause injury and death to the developing fetus. (5.1) WARNING: FETAL TOXICITY See full prescribing information for complete boxed warning. When pregnancy is detected, discontinue Exforge as soon as possible. ( 5.1 ) Drugs that act directly on the renin-angiotensin system can cause injury and death to the developing fetus.
Used for
From the label: indicationsExforge is the combination tablet of amlodipine, a dihydropyridine calcium channel blocker (DHP CCB), and valsartan, an angiotensin II receptor blocker (ARB). […]
On the market
- Earliest approval on file
- June 20, 2007
- Generic labelers
- 9 labelers
- Pharmacy cost
- $0.330 per unit
Supply and safety
- Shortage
- No current entry
- Recalls
- 20
Source: FDA drug labels via openFDA (Acetaminophen/oxycodone label of December 23, 2025, Amlodipine/valsartan label of February 17, 2026); NDC Directory, Drugs@FDA, NADAC, FDA shortages and recalls (October 8, 2026)
How do acetaminophen/oxycodone and amlodipine/valsartan differ on the record?
In FDA's classes, acetaminophen/oxycodone is an opioid agonist and amlodipine/valsartan a calcium channel blocker.
Half-life, in each label's words: Acetaminophen/oxycodone, “The plasma half-life is 1.25 to 3 hours, but may be increased by liver damage and following overdosage.”; Amlodipine/valsartan, “Elimination of amlodipine from the plasma is biphasic with a terminal elimination half-life of about 30 to 50 hours.”
Both labels carry a boxed warning; the records quote them.
Generics: acetaminophen/oxycodone since 1976; amlodipine/valsartan since 2013 (Drugs@FDA).
DEA schedule: acetaminophen/oxycodone CII; amlodipine/valsartan none.
| Acetaminophen/oxycodone | Amlodipine/valsartan | |
|---|---|---|
| Labeled for | Pain | High blood pressure |
| Pharmacologic class | Opioid Agonist | Angiotensin 2 Receptor Blocker, Calcium Channel Blocker, Dihydropyridine Calcium Channel Blocker |
| How it works (label) | n/a | Amlodipine Amlodipine is a dihydropyridine calcium channel blocker that inhibits the transmembrane influx of calcium ions into vascular smooth muscle and cardiac muscle. |
| Half-life (label) | The plasma half-life is 1.25 to 3 hours, but may be increased by liver damage and following overdosage. | Elimination of amlodipine from the plasma is biphasic with a terminal elimination half-life of about 30 to 50 hours. |
| Earliest approval on file (Drugs@FDA) | March 11, 2014 | June 20, 2007 |
| First generic approved | August 31, 1976 | March 28, 2013 |
| Generic labelers (NDC) | 29 labelers | 9 labelers |
| Pharmacy cost (NADAC, each one's most listed form; strengths differ) | $0.183 per tablet (Oxycodone-acetaminophen 7.5-325 mg tablet) | $0.330 per unit (Amlodipine-valsartan 10-160 mg) |
| 12-month price change | +2% | -35% |
| Boxed warning | Yes | Yes |
| Shortage now | A presentation being discontinued | No current entry |
| Recalls recorded | 8 | 20 |
| FAERS reports (a report is not proof of cause; counts follow how widely a medicine is used) | 23,353 | 11,192 |
| DEA schedule | CII | none |
Source: Drugs@FDA, FDA NDC Directory, CMS NADAC of October 7, 2026, FDA shortages and recalls, FAERS via openFDA (FDA files October 8, 2026)
What do the labels say about using others of their kind?
Acetaminophen/oxycodone label, drug interactionsBenzodiazepines and Other Central Nervous System (CNS) Depressants Due to additive pharmacologic effect, the concomitant use of benzodiazepines and other CNS depressants, such as benzodiazepines and other sedative hypnotics, anxiolytics, tranquilizers, muscle relaxants, general anesthetics, antipsychotics, gabapentinoids and other opioids, including alcohol, can increase the risk of hypotension, respiratory …
Source: FDA drug labels via openFDA
What next?
- Alternatives to acetaminophen/oxycodone
- every medicine labeled for the same conditions